HUP0402391A2 - Telmisartan kristályos nátriumsója, eljárás előállítására és az azt tartalmazó gyógyszerkészítmények - Google Patents

Telmisartan kristályos nátriumsója, eljárás előállítására és az azt tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0402391A2
HUP0402391A2 HU0402391A HUP0402391A HUP0402391A2 HU P0402391 A2 HUP0402391 A2 HU P0402391A2 HU 0402391 A HU0402391 A HU 0402391A HU P0402391 A HUP0402391 A HU P0402391A HU P0402391 A2 HUP0402391 A2 HU P0402391A2
Authority
HU
Hungary
Prior art keywords
production
telmisartan
sodium salt
crystalline sodium
pharmaceutical compositions
Prior art date
Application number
HU0402391A
Other languages
English (en)
Inventor
Kai Donsbach
Irmgard Hof
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7704331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0402391(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of HUP0402391A2 publication Critical patent/HUP0402391A2/hu
Publication of HUP0402391A3 publication Critical patent/HUP0402391A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgyát a 4'-{[2-propil-4-metil-6-(1-metil-benzimidazol-2-il)-benzimidazol-l-il]-metil}]-bifenil-2-karbonsav (INN: Telmisartan)képletű kristályos nátriumsója, eljárás előállítására és gyógyszerekelőállítására való alkalmazása képezi. A vegyület angiotenziaantagonista hatású. Ó
HU0402391A 2001-10-31 2002-10-11 Crystalline sodium salt of telmisartan, process for its production and pharmaceutical compositions containing it HUP0402391A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10153737A DE10153737A1 (de) 2001-10-31 2001-10-31 Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
PCT/EP2002/011394 WO2003037876A1 (de) 2001-10-31 2002-10-11 Kristallines natriumsalz des telmisartans und dessen verwendung als angiotensin antagonist

Publications (2)

Publication Number Publication Date
HUP0402391A2 true HUP0402391A2 (hu) 2005-03-29
HUP0402391A3 HUP0402391A3 (en) 2010-03-29

Family

ID=7704331

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402391A HUP0402391A3 (en) 2001-10-31 2002-10-11 Crystalline sodium salt of telmisartan, process for its production and pharmaceutical compositions containing it

Country Status (35)

Country Link
EP (1) EP1442023B1 (hu)
JP (1) JP5124076B2 (hu)
KR (1) KR100929502B1 (hu)
CN (1) CN100509789C (hu)
AR (1) AR037148A1 (hu)
AT (1) ATE370125T1 (hu)
AU (1) AU2002338886B2 (hu)
BR (1) BR0213568A (hu)
CA (1) CA2463146C (hu)
CO (1) CO5580785A2 (hu)
CY (1) CY1107504T1 (hu)
DE (2) DE10153737A1 (hu)
DK (1) DK1442023T3 (hu)
EA (1) EA007596B1 (hu)
EC (1) ECSP045089A (hu)
ES (1) ES2291505T3 (hu)
HK (1) HK1073841A1 (hu)
HR (1) HRPK20040372B3 (hu)
HU (1) HUP0402391A3 (hu)
IL (2) IL161165A0 (hu)
ME (1) MEP43608A (hu)
MX (1) MXPA04004013A (hu)
MY (1) MY129741A (hu)
NO (1) NO326465B1 (hu)
NZ (1) NZ532716A (hu)
PE (1) PE20030629A1 (hu)
PL (1) PL211462B1 (hu)
PT (1) PT1442023E (hu)
RS (1) RS50879B (hu)
SA (1) SA02230419B1 (hu)
SI (1) SI1442023T1 (hu)
TW (2) TWI341200B (hu)
UA (1) UA82833C2 (hu)
UY (1) UY27520A1 (hu)
WO (1) WO2003037876A1 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
WO2005077941A2 (en) 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
KR100908308B1 (ko) * 2004-05-05 2009-07-17 테바 파마슈티컬 인더스트리즈 리미티드 순도가 높은 칸데사르탄 실렉세틸의 제조
EP1805146A4 (en) 2004-10-18 2009-01-14 Reddys Lab Ltd Dr PROCESS FOR THE PREPARATION OF TELMISARTAN
KR20070072588A (ko) * 2004-11-03 2007-07-04 테바 파마슈티컬 인더스트리즈 리미티드 텔미사르탄 나트륨의 비정질형 및 다형
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2151450A1 (de) * 2008-07-29 2010-02-10 Sandoz AG Verfahren zur Aufarbeitung von mikrobiologisch hergestellten zyklischen Oligopeptiden
DK2432452T3 (en) 2009-05-20 2016-10-10 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutically telmisartan drink solution
WO2011002423A2 (en) 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
WO2012055941A1 (en) 2010-10-27 2012-05-03 Krka,Tovarna Zdravil, D. D., Novo Mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
US9561610B2 (en) * 2011-06-24 2017-02-07 Honda Motor Co., Ltd. Injection molding method and apparatus therefor
PL3421470T3 (pl) 2011-11-25 2021-08-02 Adverio Pharma Gmbh Podstawione 5-fluoro-1H-pirazolopirydyny w postaci krystalicznej
DK3209647T3 (da) 2014-10-21 2020-08-24 Ariad Pharma Inc Krystallinske former af 5-chlor-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl]pyrimidin-2,4-diamin
KR101872726B1 (ko) * 2016-07-28 2018-06-29 주식회사 씨트리 텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물
KR20200026975A (ko) 2017-07-07 2020-03-11 베링거잉겔하임베트메디카게엠베하 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제
JP2022517610A (ja) * 2019-01-10 2022-03-09 シーエスピーシー ゾンチー ファーマシューティカル テクノロジー（シージアチュアン）カンパニー，リミテッド 複素環化合物塩およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
ATE230263T1 (de) * 1996-02-29 2003-01-15 Novartis Erfind Verwalt Gmbh At1 rezeptor antagonist zur anregung von apoptosis
DE19901921C2 (de) * 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels

Also Published As

Publication number Publication date
CN1578772A (zh) 2005-02-09
MXPA04004013A (es) 2004-06-18
SI1442023T1 (sl) 2007-12-31
HUP0402391A3 (en) 2010-03-29
PT1442023E (pt) 2007-09-17
CA2463146A1 (en) 2003-05-08
NO326465B1 (no) 2008-12-08
HRPK20040372B3 (en) 2006-02-28
MY129741A (en) 2007-04-30
SA02230419B1 (ar) 2007-07-31
JP2005536445A (ja) 2005-12-02
JP5124076B2 (ja) 2013-01-23
CY1107504T1 (el) 2013-03-13
UA82833C2 (uk) 2008-05-26
EA200400479A1 (ru) 2004-10-28
HRP20040372A2 (en) 2004-10-31
TW200300082A (en) 2003-05-16
UY27520A1 (es) 2003-05-30
NZ532716A (en) 2007-06-29
ES2291505T3 (es) 2008-03-01
DK1442023T3 (da) 2007-11-05
PL367477A1 (en) 2005-02-21
DE10153737A1 (de) 2003-05-28
CO5580785A2 (es) 2005-11-30
KR100929502B1 (ko) 2009-12-03
KR20050035172A (ko) 2005-04-15
DE50210719D1 (de) 2007-09-27
EP1442023B1 (de) 2007-08-15
WO2003037876A1 (de) 2003-05-08
TWI333419B (en) 2010-11-21
PE20030629A1 (es) 2003-07-14
EP1442023A1 (de) 2004-08-04
AR037148A1 (es) 2004-10-27
PL211462B1 (pl) 2012-05-31
MEP43608A (en) 2011-02-10
RS50879B (sr) 2010-08-31
TWI341200B (en) 2011-05-01
IL161165A (en) 2009-12-24
HK1073841A1 (en) 2005-10-21
ECSP045089A (es) 2004-06-28
TW201034664A (en) 2010-10-01
EA007596B1 (ru) 2006-12-29
YU36304A (sh) 2006-08-17
IL161165A0 (en) 2004-08-31
BR0213568A (pt) 2004-09-08
ATE370125T1 (de) 2007-09-15
AU2002338886B2 (en) 2008-04-17
CA2463146C (en) 2011-01-25
NO20041758L (no) 2004-04-29
CN100509789C (zh) 2009-07-08

Similar Documents

Publication Publication Date Title
HUP0402391A2 (hu) Telmisartan kristályos nátriumsója, eljárás előállítására és az azt tartalmazó gyógyszerkészítmények
JO2646B1 (en) New differentiated cyclic compounds as beta - lactam inhibitors
TW200509914A (en) Pharmaceutical formulation of the telmisartan sodium salt
AR051778A2 (es) Derivados del acido dimetilaminocrotonico y procesos para supreparacion
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
RS52625B (en) FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR TREATMENT AND PREVENTION OF DISEASES AND DISEASES
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
NO20053398L (no) Farmasoytiske preparater av sertaconazol for vaginal anvendelse.
TNSN05160A1 (en) Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
NO20063268L (no) Fremgangsmate til fremstilling av 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-metoksybenzyl)quinuklidin-3-amin
MX2007007025A (es) Nuevos derivados de hidantoina como inhibidores de metaloproteinasa.
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
CY1109678T1 (el) Νεα παραγωγα 3-φαινυλπροπιονικου οξεος και χρηση αυτων ως συνδετηρες του υποδοχεα ppar-γαμμα
IL169496A0 (en) Imino acid derivatives for use as inhibitors of matrix metalloproteinases
NO20070250L (no) S-Tenatoprazol-natriummonohydratsalt og dennes anvendelse i form av en protonpumpe-inhibitor
NO20064298L (no) Piperazinureaderivater til behandling av endometriose
DE50308492D1 (de) Verbindungen, die faktor xa-aktiv t inhibieren
ATE295845T1 (de) Prucaloprid-n-oxid
HN2002000354A (es) Sales de acido citrico de un compuesto terapeutico y composiciones farmaceuticas que la contienen
BR0307039A (pt) Compostos, em particular de derivados uréias ou ésteres do ácido haloacetamidobenzóico e sua utilização para o tratamento de doenças parasitárias
SE0302853D0 (sv) Chemical compounds
ATE355298T1 (de) Fluoralkylcyclopeptidderivate mit antiintegrinwirkung
BRPI0410266A (pt) cristal, composto, processo para produzir um cristal, composição farmacêutica, inibidor de quinase, e, preventivo e/ou um remédio para doenças
MXPA04000952A (es) Sales de derivados de acido 1,2,3-4-tetrahidro-isoquinolin-2-carboxilico.

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal